SOK583A1

· Sandoz

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for SOK583A1, covering 2022-11-18 to 2024-03-26. Get the full timeline:

Most recent: Clinical Trial Update: Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration [Phase 3]

See pricing